• UCLA Health
  • myUCLAhealth
  • School of Medicine
U Magazine

U Magazine

U Magazine
  • Home
  • Current Issue
  • Centennial Campaign for UCLA Issue
  • Browse U Magazine
  • Letters to the Editor
  • Subscribe
  • Contact
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

U Magazine

Browse U Magazine

  1. Home
  2. Browse U Magazine
Share this
The Cutting Edge

Promising Drug Strategy Could Slow Neurodegeneration

Alzheimer’s disease destroys brain cells, in part, by promoting the formation of insoluble clumps that contain a protein called tau. Not only are these “tau aggregates” toxic for the cells that harbor them, but they also invade and destroy neighboring brain cells, or neurons, which speed the cognitive decline associated with Alzheimer’s. For those reasons, Alzheimer’s researchers have been intensely interested in therapies aimed at either preventing tau aggregation or blocking its spread. Now, researchers in the UCLA Department of Neurology and at the UCLA School of Nursing have reported a promising drug strategy that blocks tau transmission.

cambinol binding

A model of cambinol (small yellow structure near top center) binding to nSMase2 enzyme. Image: Kanagasabai Vadivel/UCLA Drug Discovery Lab

Using cultured cells, mouse models and protein structural analysis, researchers found that a small molecule called cambinol blocks the transfer of tau aggregates from cell to cell. The study could help lay the groundwork for therapies to treat Alzheimer’s or other dementias associated with the accumulation of tau. “More than 200 molecules have been tested as disease-modifying Alzheimer’s therapy in clinical trials, and none has yet attained the Holy Grail,” says Varghese John, PhD, associate professor of neurology. “Our paper describes a novel approach to slow Alzheimer’s progression by showing it is possible to inhibit propagation of pathologic forms of tau.”

In healthy people, tau proteins are benign building blocks of a neuron’s framework, or cytoskeleton. But in Alzheimer’s disease, tau proteins fall away from the cytoskeleton, become abnormally modified and then form insoluble “neurofibrillary tangles” that destroy cells. To make matters worse, dying cells encase tau aggregates in lipid vesicles called exosomes, which then bud off and “seed” neighboring tissues, keeping the destructive cycle going.

Researchers conducted several experiments that suggest that cambinol can subvert the “transfer” step by blocking an enzyme called nSMase2, which is essential for catalyzing production of the exosome carriers. In one, the scientists used “donor cells” that harbored tau aggregates derived from postmortem human Alzheimer’s specimens and mixed them with tau-free recipient cells.

Without cambinol, the aggregates spread from donors to recipients, mirroring what happens in the brains of people with Alzheimer’s. But when treated with cambinol, recipient cells remained tau-free when grown side by side with tau-positive donors, presumably because the drug disabled nSMase2 activity, blocking release of the tau-carrying exosomes.

The researchers also observed decreased nSMase2 catalytic activity in the brains of mice that were given cambinol orally. Dr. John says the seemingly routine experiment was an essential first step “because most drugs don’t penetrate the blood-brain barrier,” referring to the membranes that surround the central nervous system and keep drugs out of it. “Now we know we can treat animals with cambinol to determine its effect on Alzheimer’s pathology and progression.”

The research is the first to report on a model of how cambinol switches off nSMase2 catalytic activity at the atomic level, and it provides critical knowledge for medicinal chemists such as Dr. John to begin designing new drugs based on cambinol that are more potent and efficacious than the molecule itself.

“Suppression of Tau Propagation Using an Inhibitor that Targets the DK-switch of nSMase2,” Biochemical and Biophysical Research Communications, May 23, 2018

 


Previous
UCLA Scientists Use Stem Cells to Study Genetics of Germ Cell Tumors
Next
Two-cells-in-one Combo Could Be Platform to Bolster Leukemia Treatment


YOU ARE VIEWING

Winter 2019

Winter 2019
Printable PDF
IN THIS ISSUE
  • Forever Linked
  • UCLA Team Helps Create Facility for Ugandan Women Who Suffer Childbirth Injuries
  • Aggressive Prostate and Lung Cancers Are Driven by Common Mechanisms
  • Behavioral Risk Factors for Depression Vary with Age
  • UCLA Scientists Use Stem Cells to Study Genetics of Germ Cell Tumors
  • Promising Drug Strategy Could Slow Neurodegeneration
  • Two-cells-in-one Combo Could Be Platform to Bolster Leukemia Treatment
  • Cancer Treatments May Be Linked to Decline in Cognitive Performance
  • Beyond the Ivory Tower
  • Parasite Sleuth: Elissa Hallem, PhD
  • Heartbreak. And Hope
  • The Littlest Wookiee
  • The Long Road to Effectively Treat CF
  • Eat, Drink and Be Wary
  • The Doctor & the Refugee
  • Awards & Honors
  • In Memoriam
  • The Big Weekend
  • In Memoriam
  • Innovation and Courage Honored at UCLA Visionary Ball
  • $10 Million Gift Advances Programs in Women’s Health
  • Celebrating the 10th Anniversary of Ronald Reagan UCLA Medical Center
  • UCLA Mattel Children’s Hospital Hosts 19th Annual Party on the Pier
  • UCLA Operation Mend Marches Forward
  • UCLA Health Sound Body Sound Mind Celebrates 20 Years of Supporting School Fitness Programs
  • UCLA-Weizmann Institute Collaboration Advances Depression Research
  • UCLA Urology Honors Two Physicians
  • Dr. Anthony C. Arnold Named Inaugural Chair in Neurodegenerative Diseases
  • Gifts
  • A Drop in the Bucket
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest

Sign in to myUCLAhealth